中药组分复方“BZL”的筛选及其对实验性脂肪肝大鼠的作用  

Screening of Ingredients Assembling of Chinese Medicine "BZL" Prescription and Its Effect on Experimental Fatty Liver Rats

作　　者：孟胜喜[1] 胡义扬[1,2,3,4] 冯琴[1] 彭景华[1] 赵瑜[1] 陈亮[1] 徐琳[1] 刘林[1] 海亚美 梁春耕[1] 

机构地区：[1] 上海中医药大学附属曙光医院肝病研究所 上海 201203 [2]上海市高校中医内科学研究院,上海201203 [3]教育部肝肾疾病病证重点研究室,上海201203 [4]上海市中医临床重点实验室,上海201203

出　　处：《世界科学技术-中医药现代化》2014年第1期45-51,共7页Modernization of Traditional Chinese Medicine and Materia Medica-World Science and Technology

基　　金：国家自然科学基金委面上项目(81173404):基于肝脂肪代谢环节的中药组分BZL复方防治非酒精性脂肪肝作用机理研究,负责人:胡义扬;国家自然科学基金委面上项目(81384031):基于GLP-1受体相关信号通路的京尼平苷与绿原酸组合治疗非酒精性脂肪肝效应机制研究,负责人:冯琴;上海市科委上海自然基金项目(13ZR1442600):基于GLP-1受体相关信号通路的中药组分复方GC方防治非酒精性脂肪肝的机理研究,负责人:冯琴

摘　　要：目的:运用均匀设计方法,从"祛湿化瘀方"中的5个中药组分或成分中筛选出中药组分复方"BZL",并验证其对实验性脂肪肝大鼠的作用疗效。方法:采用高脂饮食诱导的大鼠脂肪肝模型,将"祛湿化瘀方"中5种有效组分或单体(绿原酸、栀子苷、姜黄素、虎杖苷、白术多糖)作为研究对象,运用均匀设计方法进行分组设计,并且灌胃给药4周,筛选指标为肝组织甘油三酯(TG)含量,通过均匀设计和回归分析而筛选出中药组分复方"BZL"方。再以同样的脂肪肝动物模型,用母方"祛湿化瘀方"和罗格列酮作为对照,测定实验大鼠的肝组织TG含量和血清ALT活性变化,观察其肝组织病理变化(HE染色和油红O染色),并进行Ridit分析,以此来验证其作用疗效。结果:经过筛选,从而得到回归方程:Y=15.083X1+5.321X2-5.186X3-16.157X4+9.35X5+17.667X3X4-8.422X1X2-6.617X3X5+16.571(X1绿原酸、X2虎杖苷、X3白术多糖、X4栀子苷、X5姜黄素),根据此方程,当绿原酸、白术多糖、栀子苷取最大剂量时出现降TG最佳效应,表明对肝组织TG含量抑制作用最佳组分组合为白术多糖(X3)、栀子苷(X4)、绿原酸(X1)组合(即"BZL方");在相同的高脂饮食诱导的脂肪肝大鼠模型中,筛选出的中药组分BZL均能可显著降低其肝组织TG含量和血清ALT活性(P<0.01),明显改善大鼠肝脏的脂肪变性。结论:通过均匀设计方法筛选出来的中药组分复方"BZL"方有显著防治高脂肪饮食诱导大鼠肝脂肪沉积和损伤的作用。This study was aimed to explore five Chinese medicine components or ingredients from Qu-Shi Hua-Y u Decoction （QSHYD） with uniform design method and screen ingredients assembling of Chinese medicine BZL pre-scription in order to verify its therapeutic effect on experimental fatty liver rats. High-fat diet was used in the estab-lishment of fatty liver rat models. Five effective ingredients （i.e., chlorogenic acid, geniposide, curcumin, polydatin and polysaccharide of Atractylodes macrocephala Koidz） of QSHYD were used as study subjects. Uniform design was applied in the grouping design. The intragastric administration was given for four weeks. The screening index was the content of liver triglyceride （TG）. The ingredients assembling of Chinese medicine BZL prescription was screened through uniform design and regression analysis. The same fatty liver animal model was used in the comparison be-tween QSHYD and rosiglitazone. The TG content in liver tissues of rats and serum ALT activity were detected. The pathological changes of liver tissues were observed （HE stain and oil red O stain） with Ridit analysis to verify its＆amp;nbsp;therapeutic effect. The results showed that through screening, the regression equation was Y = 15.083X1 ＋ 5.321X2- 5.186X3 - 16.157X4 ＋ 9.35X5 ＋ 17.667X3X4 - 8.422X1X2 - 6.617X3X5 ＋ 16.571 （X1： chlorogenic acid, X2：polydatin, X3： polysaccharide of Atractylodes macrocephala Koidz, X4： geniposide, X5： curcumin）. According to this equation, the best TG reducing effect occurred when the chlorogenic acid （X1）, polysaccharide of Atractylodes macrocephala Koidz （X3）, and geniposide （X4） were the maximum dosage. It showed that the best combination in inhibiting TG content in liver tissues was X3, X4 and X1 （i.e. BLZ prescription）. Among fatty liver rat mod-els induced with same high-fat diet, the screened Chinese medicine ingredient BZL prescription can obviously reduce its TG content in liver tissues and serum ALT activity （ P 〉 0. 01 ） .

关 键 词：中药组分复方 脂肪肝 均匀设计 筛选 

分 类 号：R285.5[医药卫生—中药学]